On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC

Proprietary Educational Format:

Activity Overview

Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy, privileged insights into optimal therapeutic selection based on the latest clinical trial data, and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.

0.75 CE Credit(s)

Target Audience

This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
  • Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC
  • Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial
  • Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting

Activity Faculty

Herbst 1200x1500

Roy S. Herbst, MD, PhD

Ensign Professor, Medicine (Medical Oncology) and Professor, Pharmacology 

Chief, Medical Oncology 

Yale Cancer Center and Smilow Cancer Hospital 

Associate Cancer Center Director, Translational Research  

Yale Cancer Center 

New Haven, CT   

Goldberg 1200x1500

Sarah B. Goldberg, MD, MPH

Associate Professor, Internal Medicine (Medical Oncology) 

Yale Cancer Center  

New Haven, CT 

Ryska 1200x1500

Prof. Aleš Ryška, MD, PhD

Head, Fingerland Department of Pathology  

Charles University, Medical Faculty  

Hradec Králové, Czech Republic